



Biotech Daily

Monday September 6, 2021

Daily news on ASX-listed biotechnology companies

- * **ASX UP, BIOTECH DOWN: OPTHEA UP 5%; OPTISCAN DOWN 11%**
- * **S&P ASX INDICES: 2 BIOTECHS UP, 2 DOWN**
- * **QUEENSLAND GRANTS FOR ANALYTICA PERICOACH MANUFACTURE**
- * **ANTEO: PERA MEDIKAL TURKEY EUGENI COVID TEST DISTRIBUTOR**
- * **LITTLE GREEN DANISH MARIJUANA; MORTEN SNEDE, TONY ROBERTS**
- * **EPSILON REQUESTS 'PARTNERSHIP' TRADING HALT**
- * **CMO DR MATTHEW MYNTTI REDUCES TO 7.1% OF NEXT SCIENCE**
- * **PERENNIAL TAKES 6.5% OF ECOFIBRE**
- * **ANTERIS APPOINTS DR CHRIS MEDURI CMO**
- * **RADIOPHARM APPOINTS RICCARDO CANEVARI CEO, M-D**
- * **CRESO APPOINTS DR MIRI HALPERIN WERNLI, WILLIAM LAY**

MARKET REPORT

The Australian stock market edged up 0.07 percent on Monday September 6, 2021, with the ASX200 up 5.6 points to 7,528.5 points. Fifteen of the Biotech Daily Top 40 stocks were up, 19 fell, four traded unchanged and two were untraded. All three Big Caps rose.

Opthea was the best, up seven cents or 5.3 percent to \$1.385, with 549,093 shares traded. Cynata, Genetic Signatures, LBT and Prescient climbed four percent or more; Pharmaxis improved 3.6 percent; Orthocell, Polynovo and Starpharma rose more than two percent; Imugene and Mesoblast were up more than one percent; with Cochlear, CSL, Cynata, Immutep, Nanosonics, Next Science and Resmed up by less than one percent.

Optiscan led the falls, down three cents or 10.7 percent to 25 cents, with 314,182 shares traded. Dimerix and Osprey lost more than eight percent; Pro Medicus shed 5.8 percent; Avita, Medical Developments, Paradigm and Proteomics fell more than four percent; Alterity, Impedimed and Telix were down more than three percent; Antisense, Neuren, Oncosil and Patrys shed two percent or more; with Clinuvel, Kazia, Universal Biosensors and Volpara down by more than one percent.

STANDARD AND POOR'S DOW JONES INDICES

Two biotechnology companies have been promoted and two demoted in changes to the Standard & Poor's ASX indices.

Standard & Poor's said that Resmed had been promoted into the ASX50 with Imugene promoted into the ASX300.

Standard & Poor's said that Avita Medical and Medical Developments International had been removed from ASX300.

Previously, Standard & Poor's has told Biotech Daily that inclusion in the indices is based solely on market capitalization.

The Biotech Daily Top 40 Index (BDI-40) is based on quality of science, benefit to human health, board and management, investment potential and market capitalization.

Standard & Poor's said the changes would be effective prior to the open of trading on September 20, 2021.

ANALYTICA

Analytica says it expects unspecified grant funding from the Queensland Government for the in-house manufacture of its intra-vaginal Pericoach for stress incontinence.

Analytica said it had taken the decision to develop its own manufacturing capability for the Pericoach system following a review of its manufacturing strategy "in contemplation of higher prospective demand ... in North America and Europe".

The company said its proposal to the Queensland Government's Advance Queensland Industry Attraction Fund involved establishing a headquarters in Maryborough, Queensland, which included the manufacture, warehousing, customer support centre, data centre, administration and training support for the Pericoach system.

Analytica said the grant included the Fund's standard terms and conditions with various project-specific grant pre-conditions to be met within six months.

The company said that grant payments were made retrospectively on the completion of agreed milestones with no obligation on Analytica to continue the project should circumstances change, and the Queensland Government had the right to terminate the grant if Analytica is not able to meet the agreed milestones.

Analytica said bringing manufacturing in-house would improve supply chain management and regulatory compliance, meet potential demand and improve market engagement.

Analytica was unchanged at 0.2 cents with 25.0 million shares traded.

ANTEOTECH

Anteo says it has appointed Pera Medikal as the Turkey distributor for its Eugeni reader and severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) test.

Anteo said the agreement with the Istanbul-based Pera Medikal was effective from September 1, 2021, with a term of three years renewable for a further two years.

The company said that Pera Medikal initially approached it in response to a European marketing campaign in 2020 and expressed interest in the Eugeni platform, in particular its sepsis tests and the company's ability to develop high performance diagnostics.

Anteo said the initial agreement was for the sales of Sars-Cov-2 antigen rapid diagnostic test with the intention of adding further distribution rights for other tests.

The company said that Turkey required all submission documents to be authenticated by Australian government agencies and this process has been initiated, with Pera Medikal arranging for a local test evaluation.

Anteotech was up one cent or 5.9 percent to 18 cents with 7.2 million shares traded.

LITTLE GREEN PHARMA

Little Green says it has imported its first Danish marijuana shipment and appointed Morten Snede chief financial officer and Tony Roberts EU general-manager.

In June, Little Green said it had commitments to raise \$27.2 million to buy a Denmark marijuana production facility from Canopy Growth Corporation for \$C20 million (\$A21.45 million) (BD: June 22, 2021).

Today, the company said it was importing about 50kg of 'Billy Buttons' tetrahydrocannabinol marijuana flowers and expected to import two more flower shipments by the end of October 2021.

Little Green said it had appointed Morten Snede, who was previously the managing director of the Danish facility as its chief financial officer.

The company said Mr Snede held a Master in Science in Commercial Law and. Business from the Copenhagen Business School.

Little Green said it had appointed the former managing-director of Tasmanian Botanics Tony Roberts as its European Union general-manager.

The company said Mr Roberts had more than 34 years' experience in an unnamed ASX listed company.

Little Green was up 2.5 cents or 3.4 percent to 76.5 cents.

EPSILON HEALTHCARE (FORMERLY THE HYDROPONICS CO)

Epsilon says it has requested a trading halt pending "an announcement with respect to ... binding agreements securing a long-term corporate partnership".

Trading will resume on September 8, 2021 or on an earlier announcement.

Epsilon last traded at 15 cents.

NEXT SCIENCE

Next Science chief medical officer Dr Matthew Myntti says he has reduced his holding from 20,657,000 shares (11.53%) to 14,068,000 shares (7.11%).

Dr Myntti said that he sold 6,585,000 shares on-market between May 5, 2021 and September 3, 2021, with the single largest sale, 6,450,000 shares for \$1.30 each.

Dr Myntti said that he was diluted in a placement in September 2020 and share plan in October 2020.

In a separate announcement, Next Science said that Dr Myntti "needed to sell the shares ... in order to meet the financial obligations pursuant to a matrimonial settlement with his former wife".

Next Science was up one cent or 0.7 percent to \$1.44.

ECOFIBRE

Perennial Value Management says it has become a substantial shareholder in Ecofibre Limited with 22,040,638 shares (6.46%).

The Sydney-based Perennial said It bought shares between May 25, 2021, and September 2, 2021, with the single largest purchase 3,277,187 shares for \$2,299,078 or 70.15 cents a share.

Ecofibre was unchanged at 75 cents.

[ANTERIS TECHNOLOGIES](#)

Anteris says it has appointed Dr Chris Meduri as its chief medical officer.

Anteris said Dr Meduri was an interventional cardiologist working on valvular heart disease and was the principal investigator of several valve trials and steering committees. The company said Dr Meduri was previously a member of its advisory board and contributed to the current development progress of its Adapt-treated Duravr bovine-tissue, single-piece, aortic valve.

Anteris said Dr Meduri had performed more than 1,500 transcatheter aortic valve replacement procedures, helped to build post-operative care pathways for transcatheter aortic valve replacement patients and developed a software application to optimize the care of patients.

According to his LinkedIn page, Dr Meduri holds a Doctor of Medicine from the Knoxville-based University of Tennessee and a Master of Public Health from Harvard.

Anteris fell 10 cents or 1.1 percent to \$8.85.

[RADIOPHARM THERANOSTICS](#)

Radiopharm says it has appointed former Novartis executive Riccardo Canevari as its chief executive officer and managing-director.

Radiopharm said the New York-based Mr Canevari was previously Novartis' chief commercial officer and was formerly the head of Novartis Oncology's breast cancer franchise.

The company said that Mr Canevari held a degree in Pharmacy, Chemistry and Pharmaceutical Technologies from Italy's University of Pavia.

Radiopharm is a public unlisted company.

[CRESO PHARMA](#)

Creso says it has appointed former chief executive officer Dr Miri Halperin Wernli as an advisor and William Lay as head of "strategy, origination and operations".

Creso said Dr Halperin Wernli was the company's founder and previously held executive positions in Europe and the US with Merck, Sharpe and Dohme, Roche, and Actelion Pharmaceuticals, and had recently been appointed a director of the New York-based, psychedelic-focused Mindmed.

The company said Mr Lay was previously an executive at Canopy Growth and previously worked for BMO Capital Markets.

Creso said it had issued Mr Lay 20,000,000 options, 15,000,000 performance rights, subject to vesting conditions and 5,000,000 shares

The company said that subject to shareholder approval, Dr Halperin Wernli would be issued 15,000,000 shares for her role as an advisor.

Creso was unchanged at 12.5 cents with 4.7 million shares traded.